AbbVie, Schizophrenia

AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays Stoic
Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug trial failed to meet their primary endpoint. AbbVie said its two phase 2 EMPOWER trials investigating emraclidine as a once-daily,
AbbVie Stock Falls on Schizophrenia Drug Study Failure
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks,
Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials
AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.
AbbVie Says Phase 2 Trials Of Emraclidine In Schizophrenia Did Not Meet Primary Endpoint
Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that its two Phase 2 EMPOWER trials investigating emraclidine as a
AbbVie's schizophrenia drug misses main goals of two trials
(Reuters) -AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading. The drug, emraclidine,
AbbVie declines after missing main goal in schizophrenia treatment trials
AbbVie (NYSE:ABBV) shares dropped about 11% after its late-stage trials investigating emraclidine as an oral monotherapy treatment for adults with schizophrenia experiencing acute exacerbation of psychotic symptoms,
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
MarketWatch50m
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie ABBV shares are down 12.4%. In a ...
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
AbbVie: 3 Positives From The Earnings Report
With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...
MarketWatch5d
AbbVie Inc. stock rises Tuesday, still underperforms market
Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading ...
bovnews7d
The AbbVie Inc Stock Thriller: Decoding the Mystery Behind ABBV’s Recent Movements
On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...
Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...
Barchart on MSN4d
Are Wall Street Analysts Bullish on AbbVie Stock?
With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.